Skip to main content
TipRanks
Go Ultimate75% OFF

Indaptus Therapeutics (INDP) Stock Price & Analysis

581 Followers

INDP Stock Chart & Stats

$3.32-$0.13(-3.77%)
At close: 4:00 PM EST
$1$2$3$4Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$3.13 - $3.60
52-Week Range
$0.92 - $5.96
Previous Close
$3.45
Volume
N/A
Average Volume (3M)
324.88K
Market Cap
$509.96M
Enterprise Value
$275.85M
Total Cash (Recent Filing)
$30.60M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
1.11
Next Earnings
May 13, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Decoy Immunotherapy Platform

A focused immunotherapy platform gives Indaptus a defined pathway for developing multiple treatment approaches in oncology. The ability to study Decoy20 both as a standalone therapy and alongside checkpoint inhibitors could broaden clinical utility and create several development opportunities over the next several quarters.

Very Low Leverage

The absence of debt limits interest obligations and refinancing exposure while the company funds clinical development. This provides greater flexibility than a highly leveraged balance sheet, allowing available capital to remain focused on research, operations, and potential program advancement.

Completed Capital Raise

Completion of the private placement provides a more concrete near-term funding resource for ongoing operations and development activities. Secured financing can reduce immediate liquidity pressure and give management additional time to advance its programs before another funding decision is required.

Bears Say

No Revenue And Persistent Losses

Indaptus remains entirely dependent on development progress rather than commercial product revenue, leaving earnings quality weak and financial performance loss-making. Without an approved revenue-generating product, the company has limited internal resources to fund operations and must rely on future financing or partnerships.

Negative Cash Generation

Persistent operating and free-cash-flow deficits indicate that the current business does not fund itself and must continue consuming capital to operate. Even with some improvement in cash burn, ongoing dependence on external funding can constrain development plans and increase shareholder financing risk.

Shareholder Dilution And Capital Erosion

The large share issuance expands the ownership base and can dilute existing holders, while the historical decline in stockholders’ equity reflects substantial capital erosion. Together, these factors show that funding operations has materially affected the equity base and may continue to do so.

Indaptus Therapeutics News

INDP FAQ

What was Indaptus Therapeutics’s price range in the past 12 months?
Indaptus Therapeutics lowest stock price was $0.92 and its highest was $5.96 in the past 12 months.
What is Indaptus Therapeutics’s market cap?
Indaptus Therapeutics’s market cap is $509.96M.
When is Indaptus Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Indaptus Therapeutics’s earnings last quarter?
Indaptus Therapeutics released its earnings results on Nov 13, 2026. The company reported -$0.01 earnings per share for the quarter.
Is Indaptus Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Indaptus Therapeutics pay dividends?
Indaptus Therapeutics does not currently pay dividends.
What is Indaptus Therapeutics’s EPS estimate?
Indaptus Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Indaptus Therapeutics have?
Indaptus Therapeutics has 153,602,580 shares outstanding.
What happened to Indaptus Therapeutics’s price movement after its last earnings report?
Indaptus Therapeutics reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went up 8.833%.
Which hedge fund is a major shareholder of Indaptus Therapeutics?
Currently, no hedge funds are holding shares in INDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology